Abstract
Once-daily tiotropium Respimat®, a long-acting anticholinergic bronchodilator, has been shown in a Phase III program to improve lung function and reduce severe exacerbation risk in severe asthma patients who remain symptomatic despite using ICS+LABA. Use of pre-trial leukotriene receptor antagonists (LTRAs) was not restricted; we analyzed whether pre-screening LTRA use affected tiotropium Respimat® efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.